Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy
Molecular Oncology · 2024-02 · 18 (2) · 291-304
DOI: 10.1002/1878-0261.13530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 05.10.2023. Verfasst von Goran Rac und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Loyola University Medical Center, Maywood, IL, USA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Intravesical therapy (IVT) is the standard of care to decrease risk of recurrence and progression for high‐grade nonmuscle‐invasive bladder cancer. However, post‐IVT recurrence remains common and the ability to risk‐stratify patients before or after IVT is limited. In this prospectively designed and accrued cohort study, we examine the utility of urinary comprehensive genomic profiling (uCGP) for predicting recurrence risk following transurethral resection of bladder tumor (TURBT) and evaluating longitudinal IVT response. Urine was collected before and after IVT instillation and uCGP testing was done using the UroAmp™ platform. Baseline uCGP following TURBT identified patients with high (61%) and low (39%) recurrence risk. At 24 months, recurrence‐free survival (RFS) was 100% for low‐risk and 45% for high‐risk patients with a hazard ratio (HR) of 9.3. Longitudinal uCGP classified patients as minimal residual disease (MRD) Negative, IVT Responder, or IVT Refractory with 24‐month RFS of 100%, 50%, and 32%, respectively. Compared with MRD Negative patients, IVT Refractory patients had a HR of 10.5. Collectively, uCGP enables noninvasive risk assessment of patients following TURBT and induction IVT. uCGP could inform surveillance cystoscopy schedules and identify high‐risk patients in need of additional therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Loyola University Medical Center, Maywood, IL, USA.
- Department of Urology, Fienberg School of Medicine, Northwestern University, Evanston, IL, USA.
- Convergent Genomics, Inc., South San Francisco, CA, USA.
- Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.
- Department of Radiology, Loyola University Medical Center, Maywood, IL, USA.
- Department of Surgery, Loyola University Medical Center, Maywood, IL, USA.
ORCID-Profile: Goran Rac, Vincent T Bicocca, Alan J Wolfe, Gopal N Gupta
Förderung
- NCI NIH HHS
Zitieren
APA
Rac, G., Patel, H. D., James, C., Desai, S., Caruso, V. M., Fischer, D. S., Lentz, P. S., Ward, C. T., Mazzarella, B. C., Phillips, K. G., Doshi, C., Bicocca, V. T., Levin, T. G., Wolfe, A. J., & Gupta, G. N. (2024). Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy. Molecular Oncology, 18(2), 291-304. https://doi.org/10.1002/1878-0261.13530
Vancouver
Rac G, Patel HD, James C, Desai S, Caruso VM, Fischer DS, et al. Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy. Molecular Oncology. 2024;18(2):291-304. doi:10.1002/1878-0261.13530
BibTeX
@article{Rac2024,
author = {Rac, Goran and Patel, Hiten D and James, Christopher and Desai, Shalin and Caruso, Vincent M and Fischer, Daniel S and Lentz, Peter S and Ward, Ceressa T and Mazzarella, Brian C and Phillips, Kevin G and Doshi, Chirag and Bicocca, Vincent T and Levin, Trevor G and Wolfe, Alan J and Gupta, Gopal N},
title = {Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy},
journal = {Molecular Oncology},
year = {2024},
volume = {18},
number = {2},
pages = {291--304},
doi = {10.1002/1878-0261.13530}
}
EUVIMED